Jesinghaus Moritz, Konukiewitz Björn, Keller Gisela, Kloor Matthias, Steiger Katja, Reiche Magdalena, Penzel Roland, Endris Volker, Arsenic Ruza, Hermann Gratiana, Stenzinger Albrecht, Weichert Wilko, Pfarr Nicole, Klöppel Günter
Institute of Pathology, Technical University of Munich, Munich, Germany.
Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Mod Pathol. 2017 Apr;30(4):610-619. doi: 10.1038/modpathol.2016.220. Epub 2017 Jan 6.
Colorectal mixed adenoneuroendocrine carcinomas are rare and clinically aggressive neoplasms with considerable morphological heterogeneity. Data on their genomic characteristics and molecular associations to either conventional colorectal adenocarcinomas or poorly differentiated neuroendocrine neoplasms is still scarce, hampering optimized patient treatment and care. Tissue from 19 colorectal mixed adenoneuroendocrine carcinomas and eight colorectal poorly differentiated neuroendocrine neoplasms (neuroendocrine carcinomas) was microdissected and subjected to next-generation sequencing using a colorectal adenocarcinoma-specific panel comprising 196 amplicons covering 32 genes linked to colorectal adenocarcinoma, and poorly differentiated neuroendocrine neoplasm tumorigenesis. Mixed adenoneuroendocrine carcinomas were also examined for microsatellite instability and MLH-1 promoter methylation status. In three mixed adenoneuroendocrine carcinomas, exocrine and endocrine components were analyzed separately. Genetic testing of colorectal mixed adenoneuroendocrine carcinomas identified 43 somatic mutations clustering in 13/32 genes. Sixteen (84%) tumors harbored at least one somatic mutation, two tumors (11%) displayed high microsatellite instability. Compared with colorectal adenocarcinomas, mixed adenoneuroendocrine carcinomas were more frequently BRAF (37%; P=0.006), and less frequently KRAS (21%; P=0.043) and APC (16%; P=0.001) mutated. Point mutations in neuroendocrine neoplasm-related genes like RB1 or RET were not detected, but one tumor harbored a heterozygous RB1 deletion. Separately analyzed adenocarcinoma and neuroendocrine carcinoma components revealed a shared mutational trunk of driver genes involved in colorectal adenocarcinoma carcinogenesis. Colorectal neuroendocrine carcinomas were similar in their mutation profile to colorectal adenocarcinomas, but compared with mixed adenoneuroendocrine carcinomas, had a higher rate of APC mutations (P=0.027). Our data indicate that colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas, suggesting that the cells giving rise to these tumors primarily have an intestinal coinage. The identification of BRAF mutations and the frequently present KRAS wild-type status principally render some mixed adenoneuroendocrine carcinomas eligible to targeted treatment strategies used for colorectal adenocarcinomas.
结直肠混合性腺神经内分泌癌是罕见的、具有临床侵袭性的肿瘤,形态学异质性相当大。关于其基因组特征以及与传统结直肠腺癌或低分化神经内分泌肿瘤的分子关联的数据仍然很少,这阻碍了对患者的优化治疗和护理。对19例结直肠混合性腺神经内分泌癌组织和8例结直肠低分化神经内分泌肿瘤(神经内分泌癌)进行显微切割,并使用包含196个扩增子、覆盖32个与结直肠腺癌及低分化神经内分泌肿瘤发生相关基因的结直肠癌特异性检测板进行二代测序。还对混合性腺神经内分泌癌进行微卫星不稳定性和MLH-1启动子甲基化状态检测。在3例混合性腺神经内分泌癌中,分别对外分泌和内分泌成分进行分析。结直肠混合性腺神经内分泌癌的基因检测发现43个体细胞突变聚集在13/32个基因中。16例(84%)肿瘤至少有1个体细胞突变,2例(11%)表现为高微卫星不稳定性。与结直肠腺癌相比,混合性腺神经内分泌癌中BRAF突变更常见(37%;P=0.006),而KRAS(21%;P=0.043)和APC(16%;P=0.001)突变较少见。未检测到RB1或RET等神经内分泌肿瘤相关基因的点突变,但有1例肿瘤存在RB1杂合缺失。分别分析的腺癌和神经内分泌癌成分显示,参与结直肠癌发生的驱动基因存在共同的突变主干。结直肠神经内分泌癌的突变谱与结直肠腺癌相似,但与混合性腺神经内分泌癌相比,APC突变率更高(P=0.027)。我们的数据表明,结直肠混合性腺神经内分泌癌和神经内分泌癌在基因上与结直肠腺癌密切相关,提示产生这些肿瘤的细胞主要起源于肠上皮。BRAF突变的鉴定以及常见的KRAS野生型状态主要使一些混合性腺神经内分泌癌有资格采用用于结直肠腺癌的靶向治疗策略。